U.S. election, rate uncertainty rattle Wall Street

Go back to U.S. election, rate uncertainty rattle Wall Street

Valeant (VRX) 3Q Earnings Preview: Underlying RX Trends Remain Weak - Wells Fargo

November 1, 2016 7:54 AM EDT

Wells Fargo analyst David Maris issued a Q3 preview of Valeant Pharmaceuticals (NYSE: VRX), saying while the company should have some tailwinds for 3Q including price increases, cost cuts, and a now fixed Walgreens deal; however, Valeant's underlying U.S. prescription trends remain... More